Showing 1 - 20 results of 20 for search 'Philip J. Mease', query time: 0.04s Refine Results
  1. 1
    Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project

    Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project by Philip J Mease, Fabian Proft, Murat Torgutalp, Shikha Singla, Andre Ribeiro

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

    Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry by Philip J. Mease, Miroslawa Nowak, Jiyoon Choi, Thomas Lehman, Antoine Sreih, Kaylee Ho, Nicole Middaugh, Alexis Ogdie

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives

    What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives by Philip J. Mease, M. Elaine Husni, Evan Siegel, Daniel E. Furst, Melissa Mcilraith, Vibeke Strand, M. Cameron Hay

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

    Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized c... by Dafna D. Gladman, Peter Nash, Philip J. Mease, Oliver FitzGerald, Stephanie Duench, Mary Jane Cadatal, Karim R. Masri

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry

    Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study fro... by Philip J Mease, Jeffrey D Greenberg, Chitra Karki, Mei Liu, YouFu Li, Bernice Gershenson, Hua Feng, Peter Hur

    Published 2019-06-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study

    Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study by Philip J Mease, Joachim Sieper, Josef S Smolen, Dafna Gladman, H Patrick McNeil, Maja Hojnik, Pascal Nurwakagari, John Weinman

    Published 2019-06-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis

    Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis by Philip J Mease, Daniel E Furst, Jeffrey R Lisse, Christophe Sapin, Kirstin Griffing, Sarah Ross, Paulo Reis, Aisha Vadhariya, Soumya Reddy

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial

    Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial by Philip J Mease, Iain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, Manuela Le Bars, Subhashis Banerjee, Harris A Ahmad, Yedid Elbez

    Published 2019-06-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

    Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial by Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, Luminita Pricop

    Published 2018-08-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

    Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study by Laure Gossec, Peter Nash, Philip J Mease, Emmanouil Rampakakis, Laura C Coates, Philip S Helliwell, Alexa P Kollmeier, Xie L Xu, May Shawi, Miriam Zimmermann, Natalie J Shiff

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to con... by Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Daniela Graham, Cunshan Wang, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu

    Published 2019-05-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

    Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, ran... by Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu, Linda Chen, Elizabeth Kudlacz, Joseph Wu

    Published 2019-06-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

    Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies by Robert Landewé, Ana-Maria Orbai, Philip J Mease, Denis Poddubnyy, Lianne S Gensler, Vishvesh Shende, Richard B Warren, Luke Peterson, Alexander Marten, Ute Massow, Katy White, Barbara Ink, Rajan Bajracharya, Myriam Manente

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study

    Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3,... by Philip J. Mease, Xenofon Baraliakos, Vinod Chandran, Enrique R. Soriano, Peter Nash, Atul Deodhar, Emmanouil Rampakakis, Natalie J. Shiff, Soumya D. Chakravarty, May Shawi, Joseph F. Merola, Iain B. McInnes

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry

    Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry by Philip J Mease, Jeffrey D Greenberg, Carol J Etzel, William J Huster, Talia M Muram, April W Armstrong, Jeffrey R Lisse, Sabrina Rebello, Rhiannon Dodge, Mwangi James Murage, William N Malatestinic

    Published 2019-06-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

    Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms by Joseph F. Merola, Philip J. Mease, April W. Armstrong, Vibeke Strand, Thomas Lehman, Stefan Varga, Jiyoon C. Choi, Brandon Becker, Yichen Zhong, Matthew J. Colombo, Diamant Thaçi, Androniki Bili, Alice B. Gottlieb

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

    Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

    Published 2024-08-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

    Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

    Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... by Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Yoshiya Tanaka, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: